Immunotherapy plus radiation for operable liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 1 study tests radiation treatment (SIRT) together with two immunotherapy drugs (tremelimumab and durvalumab) in people with liver cancer that can be surgically removed. It aims to see whether this combination is safe and can work well before/around surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (HCC) confirmed by biopsy or, in some cirrhosis cases, by specific scan findings.
- Your cancer is considered resectable (can be surgically removed) and your liver is working well (Child-Pugh A) with early-stage limits.
- You have not received any prior treatment for liver cancer.
- Your scans show measurable disease (doctors can track it on imaging).
- Your overall health is good enough for treatment (ECOG 0–1) and your weight is over 30 kg.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies durvalumab and tremelimumab (immunotherapy medicines) in people with resectable early or intermediate-stage liver cancer (HCC). It aims to see how well these medicines work before/around the time of surgery, and whether they can improve outcomes.
This trial tests whether combining an immunotherapy drug with a special type of liver radiation (yttrium-90) can control metastatic hepatocellular carcinoma (liver cancer that has spread). It may help by boosting your immune system and shrinking liver tumors at the same time.
This trial tests a targeted radiation treatment (SIRT) for people with liver cancer that is still confined to one side of the liver and has not been treated before. The goal is to see if SIRT can shrink the tumor enough to make surgical removal possible.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.